Search

Your search keyword '"Zhang, Vickie"' showing total 143 results
Start Over Author "Zhang, Vickie"
143 results on '"Zhang, Vickie"'

1. Evaluating the Surrogate Index as a Decision-Making Tool Using 200 A/B Tests at Netflix

Author

Zhang, Vickie, Zhao, Michael, Dimakopoulou, and Maria, Le, Anh, and Kallus, Nathan

Subjects
Statistics - Applications, Statistics - Methodology
Abstract

Surrogate index approaches have recently become a popular method of estimating longer-term impact from shorter-term outcomes. In this paper, we leverage 1098 test arms from 200 A/B tests at Netflix to empirically investigate to what degree would decisions made using a surrogate index utilizing 14 days of data would align with those made using direct measurement of day 63 treatment effects. Focusing specifically on linear "auto-surrogate" models that utilize the shorter-term observations of the long-term outcome of interest, we find that the statistical inferences that we would draw from using the surrogate index are ~95% consistent with those from directly measuring the long-term treatment effect. Moreover, when we restrict ourselves to the set of tests that would be "launched" (i.e. positive and statistically significant) based on the 63-day directly measured treatment effects, we find that relying instead on the surrogate index achieves 79% and 65% recall.

Published
2023

3. Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model

Author

Qin, Hecong, Zhang, Vickie, Bok, Robert A, Santos, Romelyn Delos, Cunha, J Adam, Hsu, I-Chow, Santos Bs, Justin Delos, Lee, Jessie E, Sukumar, Subramaniam, Larson, Peder EZ, Vigneron, Daniel B, Wilson, David M, Sriram, Renuka, and Kurhanewicz, John

Subjects
Cancer, Urologic Diseases, Biomedical Imaging, Prostate Cancer, Aging, Rare Diseases, Animals, Carbon Isotopes, Disease Models, Animal, Dose-Response Relationship, Radiation, Magnetic Resonance Imaging, Male, Mice, Perfusion Imaging, Prostatic Neoplasms, Pyruvic Acid, Time Factors, Treatment Outcome, Urea, Other Physical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo investigate use of a novel imaging approach, hyperpolarized (HP) 13C magnetic resonance imaging (MRI) for simultaneous metabolism and perfusion assessment, to evaluate early and dose-dependent response to radiation therapy (RT) in a prostate cancer mouse model.Methods and materialsTransgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice (n = 18) underwent single-fraction RT (4-14 Gy steep dose across the tumor) and were imaged serially at pre-RT baseline and 1, 4, and 7 days after RT using HP 13C MRI with combined [1-13C]pyruvate (metabolic active agent) and [13C]urea (perfusion agent), coupled with conventional multiparametric 1H MRI including T2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging. Tumor tissues were collected 4 and 7 days after RT for biological correlative studies.ResultsWe found a significant decrease in HP pyruvate-to-lactate conversion in tumors responding to RT, with concomitant significant increases in HP pyruvate-to-alanine conversion and HP urea signal; the opposite changes were observed in tumors resistant to RT. Moreover, HP lactate change was dependent on radiation dose; tumor regions treated with higher radiation doses (10-14 Gy) exhibited a greater decrease in HP lactate signal than low-dose regions (4-7 Gy) as early as 1 day post-RT, consistent with lactate dehydrogenase enzyme activity and expression data. We also found that HP [13C]urea MRI provided assessments of tumor perfusion similar to those provided by 1H dynamic contrast-enhanced MRI in this animal model. However, apparent diffusion coefficien , a conventional 1H MRI functional biomarker, did not exhibit statistically significant changes within 7 days after RT.ConclusionThese results demonstrate the ability of HP 13C MRI to monitor radiation-induced physiologic changes in a timely and dose-dependent manner, providing the basic science premise for further clinical investigation and translation.

Published
2020

6. Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML

Author

Choe, Sung, Wang, Hongfang, DiNardo, Courtney D., Stein, Eytan M., de Botton, Stéphane, Roboz, Gail J., Altman, Jessica K., Mims, Alice S., Watts, Justin M., Pollyea, Daniel A., Fathi, Amir T., Tallman, Martin S., Kantarjian, Hagop M., Stone, Richard M., Quek, Lynn, Konteatis, Zenon, Dang, Lenny, Nicolay, Brandon, Nejad, Parham, Liu, Guowen, Zhang, Vickie, Liu, Hua, Goldwasser, Meredith, Liu, Wei, Marks, Kevin, Bowden, Chris, Biller, Scott A., Attar, Eyal C., and Wu, Bin

Published
2020
Full Text
View/download PDF

9. What should we do with bad feelings? Negative affects, impotential responses.

Author

Dekeyser, Thomas, Zhang, Vickie, and Bissell, David

Subjects
*EMOTIONS, *ETHICS
Abstract

Bad feelings are everywhere. When faced with this situation in our empirical encounters or conceptual analyses, most socio-spatial research is committed to making things right again, with an eye to unleashing new potentials for action by repairing bad feeling. Yet this 'ethics of rehabilitation' assumes both the inherent possibility and ethical desirability of working away those affects that are deemed to be 'negative'. We argue that this activating process risks delegitimising, in possibly troubling or violent ways, the ethical validity of both incapacities (when one is unable to act) and negative capacities (when one decides to not act). Instead of a rehabilitative ethics, we propose an 'ethics of impotentiality' that suspends the urge to activate negative affects, offering a radically situated ethical relation that is neither didactic nor moralising, refuses any easy distinction between empowering and disempowering affects, and allows for subjects to stay with inaction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Quantitative metabolic profiles of 2nd and 3rd trimester human amniotic fluid using 1H HR-MAS spectroscopy

Author

Cohn, Brad R., Joe, Bonnie N., Zhao, Shoujun, Kornak, John, Zhang, Vickie Y., Iman, Rahwa, Kurhanewicz, John, Vahidi, Kiarash, Yu, Jingwei, Caughey, Aaron B., and Swanson, Mark G.

Subjects
Medicine & Public Health, Health Informatics, Biomedical Engineering, Solid State Physics, Computer Appl. in Life Sciences, Imaging / Radiology, Electronic reference to access in vivo concentrations (ERETIC), Gestational age, High-resolution magic angle spinning (HR-MAS), Spectroscopy, High-resolution quantum estimation (HR-QUEST), Human amniotic fluid
Abstract

To establish and compare normative metabolite concentrations in 2nd and 3rd trimester human amniotic fluid samples in an effort to reveal metabolic biomarkers of fetal health and development.Twenty-one metabolite concentrations were compared between 2nd (15–27 weeks gestation, N = 23) and 3rd (29–39 weeks gestation, N = 27) trimester amniotic fluid samples using 1H high resolution magic angle spinning (HR-MAS) spectroscopy. Data were acquired using the electronic reference to access in vivo concentrations method and quantified using a modified semi-parametric quantum estimation algorithm modified for high-resolution ex vivo data.Sixteen of 21 metabolite concentrations differed significantly between 2nd and 3rd trimester groups. Betaine (0.00846±0.00206 mmol/kg vs. 0.0133±0.0058 mmol/kg, P < 0.002) and creatinine (0.0124±0.0058 mmol/kg vs. 0.247±0.011 mmol/kg, P < 0.001) concentrations increased significantly, while glucose (5.96±1.66 mmol/kg vs. 2.41±1.69 mmol/kg, P < 0.001), citrate (0.740±0.217 mmol/kg vs. 0.399±0.137 mmol/kg, P < 0.001), pyruvate (0.0659±0.0103 mmol/kg vs. 0.0299±0.286 mmol/kg, P < 0.001), and numerous amino acid (e.g. alanine, glutamate, isoleucine, leucine, lysine, and valine) concentrations decreased significantly with advancing gestation. A stepwise multiple linear regression model applied to 50 samples showed that gestational age can be accurately predicted using combinations of alanine, glucose and creatinine concentrations.These results provide key normative data for 2nd and 3rd trimester amniotic fluid metabolite concentrations and provide the foundation for future development of magnetic resonance spectroscopy (MRS) biomarkers to evaluate fetal health and development.

Published
2009

11. Quantitative metabolic profiles of 2nd and 3rd trimester human amniotic fluid using (1)H HR-MAS spectroscopy.

Author

Cohn, Brad R, Joe, Bonnie N, Zhao, Shoujun, Kornak, John, Zhang, Vickie Y, Iman, Rahwa, Kurhanewicz, John, Vahidi, Kiarash, Yu, Jingwei, Caughey, Aaron B, and Swanson, Mark G

Subjects
Amniotic Fluid, Humans, Betaine, Citric Acid, Pyruvic Acid, Creatinine, Glucose, Alanine, Magnetic Resonance Spectroscopy, Pregnancy, Pregnancy Trimester, Second, Pregnancy Trimester, Third, Adult, Female, Metabolome, Young Adult, Biomarkers, Electronic reference to access in vivo concentrations (ERETIC) Gestational age, High-resolution magic angle spinning, Spectroscopy, High-resolution quantum estimation, Human amniotic fluid, Pregnancy Trimester, Second, Third, Nuclear Medicine & Medical Imaging
Abstract

ObjectTo establish and compare normative metabolite concentrations in 2nd and 3rd trimester human amniotic fluid samples in an effort to reveal metabolic biomarkers of fetal health and development.Materials and methodsTwenty-one metabolite concentrations were compared between 2nd (15-27 weeks gestation, N = 23) and 3rd (29-39 weeks gestation, N = 27) trimester amniotic fluid samples using (1)H high resolution magic angle spinning (HR-MAS) spectroscopy. Data were acquired using the electronic reference to access in vivo concentrations method and quantified using a modified semi-parametric quantum estimation algorithm modified for high-resolution ex vivo data.ResultsSixteen of 21 metabolite concentrations differed significantly between 2nd and 3rd trimester groups. Betaine (0.00846+/-0.00206 mmol/kg vs. 0.0133+/-0.0058 mmol/kg, P < 0.002) and creatinine (0.0124+/-0.0058 mmol/kg vs. 0.247+/-0.011 mmol/kg, P < 0.001) concentrations increased significantly, while glucose (5.96+/-1.66 mmol/kg vs. 2.41+/-1.69 mmol/kg, P < 0.001), citrate (0.740+/-0.217 mmol/kg vs. 0.399+/-0.137 mmol/kg, P < 0.001), pyruvate (0.0659+/-0.0103 mmol/kg vs. 0.0299+/-0.286 mmol/kg, P < 0.001), and numerous amino acid (e.g. alanine, glutamate, isoleucine, leucine, lysine, and valine) concentrations decreased significantly with advancing gestation. A stepwise multiple linear regression model applied to 50 samples showed that gestational age can be accurately predicted using combinations of alanine, glucose and creatinine concentrations.ConclusionThese results provide key normative data for 2nd and 3rd trimester amniotic fluid metabolite concentrations and provide the foundation for future development of magnetic resonance spectroscopy (MRS) biomarkers to evaluate fetal health and development.

Published
2009

12. Recent Use of Pediatric Extrapolation in Pediatric Drug Development in US.

Author

Ye, Jingjing, Zhang, Vickie, Strimenopoulou, Foteini, Zhao, Yihua, Pan, Haitao, Shabbout, Mayadah, and Gamalo, Margaret

Subjects
*EXTRAPOLATION, *DRUG development, *BIOLOGICAL products, *DRUG approval, *COMMUNICABLE diseases, *NEUROSCIENCES
Abstract

The regulatory standards of the United States Food and Drug Administration (FDA) require substantial evidence of effectiveness from adequate and well-controlled trials, for drugs developed in both adults and children. However, when scientifically justified, relying on extrapolation may be acceptable. Historically, the FDA's extrapolation approach was based on draft guidance published in 2014, which introduced the categories of full, partial, and no extrapolation. The European Medicines Agency (EMA) took a different view on pediatric extrapolation. To better understand the use of extrapolation to support pediatric drug development and approval, we reviewed the pediatric labeling changes published by the FDA, focusing on the labeling updates between 1/1/2015 and 7/31/2021, the period where the extrapolation approach is in transition to harmonize with the EMA. Within this time window, among the 265 drugs and biological products with pediatric labeling changes, 169 (63.8%) were identified where extrapolation was used. This includes 64 (24.2%) labeling changes, where full extrapolation was used, and 105 (39.6%) labeling changes, where partial extrapolation was used. The major disease areas that extrapolation was used include neuroscience (40/53, 75.5%) and infectious disease (20/28, 71.4%). The extrapolation approach was identified in terms of source population beyond the use of adult as well as extrapolation from clinical trials conducted in the same drug class. The use of extrapolation increased the rates of new and expanded pediatric indication in the period. This review gives the most recent landscape of pediatric labeling changes using extrapolation. With the released ICH (International Council for Harmonization) E11A guidance in April 2022, the paper also provides insights for future pediatric drug development programs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation

Author

Stein, Eytan M., primary, DiNardo, Courtney D., additional, Fathi, Amir T., additional, Mims, Alice S., additional, Savona, Michael R., additional, Stein, Anthony S., additional, Stone, Richard M., additional, Winer, Eric S., additional, Seet, Christopher S., additional, Döhner, Hartmut, additional, Pollyea, Daniel A., additional, McCloskey, James K, additional, Odenike, Olatoyosi, additional, Lowenberg, Bob, additional, Ossenkoppele, Gert J., additional, Patel, Prapti, additional, Roshal, Mikhail, additional, Frattini, Mark G., additional, Lersch, Frederik, additional, Nabhan, Salah, additional, Almon, Caroline, additional, Saatcioglu, Duygu, additional, Zhang, Vickie, additional, Cooper, Michael, additional, Kantarjian, Hagop, additional, and Tallman, Martin S., additional

Published
2021
Full Text
View/download PDF

19. MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study

Author

DiNardo, Courtney D, primary, Foran, James M, additional, Watts, Justin M, additional, Stein, Eytan M, additional, de Botton, Stéphane, additional, Fathi, Amir T, additional, Prince, Gabrielle T, additional, Stein, Anthony S, additional, Stone, Richard M, additional, Patel, Prapti A, additional, Roboz, Gail J, additional, Arellano, Martha L, additional, Erba, Harry P, additional, Pigneux, Arnaud, additional, Stuart, Robert K, additional, Thomas, Xavier, additional, Uy, Geoffrey L, additional, Lemieux, Ian R, additional, Zhang, Vickie, additional, Kapsalis, Stephanie M, additional, Garcia-Manero, Guillermo, additional, and Sallman, David A, additional

Published
2021
Full Text
View/download PDF

20. Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study

Author

DiNardo, Courtney D, primary, Foran, James M, additional, Watts, Justin M, additional, Stein, Eytan M, additional, De Botton, Stéphane, additional, Fathi, Amir T, additional, Prince, Gabrielle T, additional, Stein, Anthony S, additional, Stone, Richard M, additional, Patel, Prapti A, additional, Roboz, Gail J, additional, Arellano, Martha L, additional, Erba, Harry P, additional, Pigneux, Arnaud, additional, Stuart, Robert K, additional, Thomas, Xavier, additional, Uy, Geoffrey L, additional, Lemieux, Ian R, additional, Zhang, Vickie, additional, Kapsalis, Stephanie M, additional, Garcia-Manero, Guillermo, additional, and Sallman, David A, additional

Published
2021
Full Text
View/download PDF

21. Monitoring Tumor Response of Prostate Cancer to Radiation Therapy by Multi-parametric 1H and Hyperpolarized 13C Magnetic Resonance Imaging

Author

Zhang, Vickie Yi

Subjects
Biomedical engineering
Abstract

Radiation therapy is one of the most common curative therapies for patients with localized prostate cancer, but despite excellent success rates, a significant number of patients suffer post- treatment cancer recurrence. The accurate characterization of early tumor response remains a major challenge for the clinical management of these patients. Multi-parametric MRI/1H MR spectroscopy imaging (MRSI) has been shown to increase the diagnostic performance in evaluating the effectiveness of radiation therapy. 1H MRSI can detect altered metabolic profiles in cancerous tissue. In this project, the concentrations of prostate metabolites from snap-frozen biopsies of recurrent cancer after failed radiation therapy were correlated with histopathological findings to identify quantitative biomarkers that predict for residual aggressive versus indolent cancer. The total choline to creatine ratio was significantly higher in recurrent aggressive versus indolent cancer, suggesting that use of a higher threshold tCho/Cr ratio in future in vivo 1H MRSI studies could improve the selection and therapeutic planning for patients after failed radiation therapy.Varying radiation doses may cause a diverse effect on prostate cancer micro-environment and metabolism, which could hold the key to improving treatment protocols for individual patients. The recent development and clinical translation of hyperpolarized 13C MRI have provided the ability to monitor both changes in the tumor micro-environment and its metabolism using a multi-probe approach, [1-13C]pyruvate and 13C urea, combined with 1H Multi-parametric MRI. In this thesis, hyperpolarized 13C MRI, 1H dynamic contrast enhancement, and diffusion weighted imaging were used to identify early radiation dose response in a transgenic prostate cancer model. Hyperpolarized pyruvate to lactate metabolism significantly decreased in a dose dependent fashion by 1 day after radiation therapy, prior to any changes observed using 1H DCE and diffusion weighted imaging. Hyperpolarized 13C urea and 1H DCE both show increase in perfusion/permeability by 4 days post-radiation. In tumor region treated with high dose radiation, ADC values significantly increased post-radiation, suggesting a decrease in cellular density. These dose dependent changes can be used as markers of early tumor response to the impact of increasing doses of radiation therapy. In addition, a spectral-spatial pulse sequence was developed for the 14T to dynamically observe kinetic information in a transgenic prostate cancer model before and after radiation therapy. A novel modeling approach was proposed to parameterize perfusion in the kinetic modeling of pyruvate to lactate conversion for better characterization of pyruvate metabolism. Unlike single time point HP 13C urea imaging, quantitative pharmacokinetic parameters such as blood flow and extracellular extravascular volume fraction can be extracted from dynamic acquisitions. Blood flow measured by hyperpolarized 13C urea was highly correlated with Ktrans measured by 1H DCE, suggesting hyperpolarized urea might be able to provide similar information as 1H DCE.The results of this thesis show that Multi-parametric MRI, including functional MRI, 1H MRSI, and hyperpolarized 13C, holds great potential for evaluating early tumor response to radiation therapy of prostate cancer. The findings of this thesis will be useful in designing future studies for using combined Multi-parametric 1H and hyperpolarized 13C MRI to improve planning and assessing radiation therapy in individual prostate cancer patients.

Published
2014

23. Turbulence, habit and desire: life after two coal mine closures

Author

Zhang, Vickie and Zhang, Vickie

Abstract

This thesis investigates the experiences of workers and their families as they navigate disruptions to everyday life caused by workplace closure and job loss. Situated in the boom-and-bust world of extractive industry, it draws on qualitative fieldwork at two recently closed coal mines in Australia and China to explore the twists and turns of life after loss in restructuring economies. Picking up people’s lives several years after the mine closures, this thesis traces the cascading chain of changes catalysed by the event of closure. It explores how circumstances of life come to press upon bodies in the wake of loss, and how these intensities can come to reshape how people experience the world. It ultimately asks how people might weather the crisis of loss such that they regain a sense of life as an ‘ordinary’ timespace, reorienting from the past to the future. To do this, this thesis approaches loss as a non-relational force of interruption, showing how loss decomposes existing relations and exposes people to an unknown present. Drawing on postphenomenological theories of bodily change, it then tracks the shifts in concerns, anxieties, and orientations that emerge in this timespace of vulnerability and exposure. These processes of change are explored through three empirical chapters on the forces of turbulence, habit and desire. Turbulence shows how loss can bring ordinary life into disorder, leaving people exposed to the intrusions of unfamiliar and often unmanageable conditions. Habit suggests how melancholy durations of life can redraw everyday existence, allowing bodies to pick up different lines of the past to make sense of the present. Finally, desire describes how encounters after loss might begin to mobilise processes of repair, reorienting people from a lost past towards an unfolding future. By examining the relationship between self and other in the constitution of subjectivity, this thesis shows how transformations of the subject can come about through af

Published
2020

25. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Author

DiNardo, Courtney D., primary, Stein, Anthony S., additional, Stein, Eytan M., additional, Fathi, Amir T., additional, Frankfurt, Olga, additional, Schuh, Andre C., additional, Döhner, Hartmut, additional, Martinelli, Giovanni, additional, Patel, Prapti A., additional, Raffoux, Emmanuel, additional, Tan, Peter, additional, Zeidan, Amer M., additional, de Botton, Stéphane, additional, Kantarjian, Hagop M., additional, Stone, Richard M., additional, Frattini, Mark G., additional, Lersch, Frederik, additional, Gong, Jing, additional, Gianolio, Diego A., additional, Zhang, Vickie, additional, Franovic, Aleksandra, additional, Fan, Bin, additional, Goldwasser, Meredith, additional, Daigle, Scott, additional, Choe, Sung, additional, Wu, Bin, additional, Winkler, Thomas, additional, and Vyas, Paresh, additional

Published
2021
Full Text
View/download PDF

26. Longitudinal Molecular Profiling in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib

Author

Choe, Sung, primary, Wang, Hongfang, additional, Roboz, Gail J., additional, DiNardo, Courtney D., additional, Stein, Eytan M., additional, Mims, Alice S., additional, Prince, Gabrielle T., additional, Watts, Justin M., additional, Fan, Bin, additional, Nejad, Parham, additional, Zhang, Vickie, additional, Liu, Hua, additional, Attar, Eyal C., additional, Wu, Bin, additional, and Stone, Richard M., additional

Published
2020
Full Text
View/download PDF

27. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia

Author

Roboz, Gail J., primary, DiNardo, Courtney D., primary, Stein, Eytan M., primary, de Botton, Stéphane, primary, Mims, Alice S., primary, Prince, Gabrielle T., primary, Altman, Jessica K., primary, Arellano, Martha L., primary, Donnellan, Will, primary, Erba, Harry P., primary, Mannis, Gabriel N., primary, Pollyea, Daniel A., primary, Stein, Anthony S., primary, Uy, Geoffrey L., primary, Watts, Justin M., primary, Fathi, Amir T., primary, Kantarjian, Hagop M., primary, Tallman, Martin S., primary, Choe, Sung, primary, Dai, David, primary, Fan, Bin, primary, Wang, Hongfang, primary, Zhang, Vickie, primary, Yen, Katharine E., primary, Kapsalis, Stephanie M., primary, Hickman, Denice, primary, Liu, Hua, primary, Agresta, Samuel V., primary, Wu, Bin, primary, Attar, Eyal C., primary, and Stone, Richard M., primary

Published
2020
Full Text
View/download PDF

29. Negativity: space, politics and affects.

Author

Dekeyser, Thomas, Secor, Anna, Rose, Mitch, Bissell, David, Zhang, Vickie, and Romanillos, Jose Luis

Subjects
GEOGRAPHERS, PRACTICAL politics, ANNUAL meetings
Abstract

This paper reflects on the status of 'negativity' in contemporary social and geographical thought. Based on a panel discussion held at the American Association of Geographers Annual Meeting 2021, each contributor discusses what negativity means to them, and considers its various legacies and potential future trajectories. Along the way, the contributors offer ways of attending to negative spaces (voids, abysses, absences), affects (vulnerabilities, sad passions, incapacities, mortality) and politics (impasses, refusals, irreparabilities). However, rather than defining negativity narrowly, the paper stays with the diversity of work on negativity being undertaken by geographers and other scholars, discussing how varying perspectives expand or dismantle particular elements within spatial theory. Collectively, the contributors argue for paying attention to negativity as the faltering, failure or impossibility of relations between body and world, thus situating it in conversation with relational thought, vitalist philosophies and affirmative ethics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

Author

Foran, James M., primary, DiNardo, Courtney D., additional, Watts, Justin M., additional, Stein, Eytan M., additional, De Botton, Stephane, additional, Fathi, Amir T., additional, Prince, Gabrielle T., additional, Stein, Anthony, additional, Stone, Richard M., additional, Patel, Prapti A., additional, Tallman, Martin S., additional, Choe, Sung, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Fan, Bin, additional, Yen, Katharine E., additional, Oluyadi, Abdulafeez, additional, Winkler, Thomas, additional, Hickman, Denice, additional, Agresta, Samuel V., additional, Liu, Hua, additional, Wu, Bin, additional, Attar, Eyal C., additional, and Kantarjian, Hagop M., additional

Published
2019
Full Text
View/download PDF

31. High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Author

Daigle, Scott R., primary, Choe, Sung, additional, Quek, Lynn, additional, DiNardo, Courtney D., additional, Stein, Anthony, additional, Stein, Eytan M., additional, Fathi, Amir T., additional, Frankfurt, Olga, additional, Schuh, Andre C., additional, Kantarjian, Hagop M., additional, Zhang, Vickie, additional, Winkler, Thomas, additional, Vyas, Paresh, additional, and Wu, Bin, additional

Published
2019
Full Text
View/download PDF

32. AGILE: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Author

Fernandez, Pau Montesinos, primary, Recher, Christian, additional, Doronin, Vadim, additional, Calado, Rodrigo T., additional, Jang, Jun Ho, additional, Miyazaki, Yasushi, additional, Wang, Jianxiang, additional, Gianolio, Diego A, additional, Daigle, Scott R., additional, Winkler, Thomas, additional, Zhang, Vickie, additional, and Paschka, Peter, additional

Published
2019
Full Text
View/download PDF

33. Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Author

Wang, Hongfang, primary, Choe, Sung, primary, DiNardo, Courtney D., primary, Stein, Eytan M., primary, de Botton, Stéphane, primary, Fathi, Amir T., primary, Tallman, Martin S., primary, Kantarjian, Hagop M., primary, Stone, Richard M., primary, Quek, Lynn, primary, Zhang, Vickie, primary, Liu, Hua, primary, Attar, Eyal C., primary, and Wu, Bin, primary

Published
2019
Full Text
View/download PDF

34. Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia

Author

Choe, Sung, primary, Wang, Hongfang, primary, DiNardo, Courtney D., primary, Stein, Eytan M., primary, De Botton, Stephane, primary, Fathi, Amir T., primary, Tallman, Martin S., primary, Kantarjian, Hagop M., primary, Stone, Richard M., primary, Quek, Lynn, primary, Konteatis, Zenon, primary, Dang, Lenny, primary, Zhang, Vickie, primary, Liu, Hua, primary, Attar, Eyal C., primary, and Wu, Bin, primary

Published
2019
Full Text
View/download PDF

35. Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study

Author

DiNardo, Courtney D., primary, Roboz, Gail J., additional, Stein, Eytan M., additional, de Botton, Stéphane, additional, Mims, Alice S., additional, Prince, Gabrielle T., additional, Altman, Jessica K., additional, Arellano, Martha L., additional, Donnellan, Will, additional, Erba, Harry P., additional, Mannis, Gabriel N., additional, Pollyea, Daniel A., additional, Stein, Anthony S., additional, Uy, Geoffrey L., additional, Watts, Justin M., additional, Fathi, Amir T., additional, Kantarjian, Hagop M., additional, Tallman, Martin S., additional, Choe, Sung, additional, Dai, David, additional, Fan, Bin, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Yen, Katharine E., additional, Kapsalis, Stephanie M., additional, Hickman, Denice, additional, Liu, Hua, additional, Agresta, Samuel V., additional, Wu, Bin, additional, Attar, Eyal C., additional, and Stone, Richard M., additional

Published
2019
Full Text
View/download PDF

36. Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 Study

Author

DiNardo, Courtney D., primary, Foran, James M., additional, Watts, Justin M., additional, Stein, Eytan M., additional, de Botton, Stéphane, additional, Fathi, Amir T., additional, Prince, Gabrielle T., additional, Stein, Anthony S., additional, Stone, Richard M., additional, Patel, Prapti A., additional, Tallman, Martin S., additional, Choe, Sung, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Dai, David, additional, Fan, Bin, additional, Yen, Katherine E., additional, Kapsalis, Stephanie K., additional, Hickman, Denice, additional, Agresta, Samuel V., additional, Liu, Hua, additional, Wu, Bin, additional, Attar, Eyal C., additional, and Kantarjian, Hagop M., additional

Published
2019
Full Text
View/download PDF

37. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

Author

DiNardo, Courtney D., primary, Stein, Anthony S., additional, Stein, Eytan M., additional, Fathi, Amir T., additional, Frankfurt, Olga, additional, Schuh, Andre C., additional, Döhner, Hartmut, additional, Martinelli, Giovanni, additional, Raffoux, Emmanuel, additional, Tan, Peter, additional, Zeidan, Amer, additional, de Botton, Stéphane, additional, Kantarjian, Hagop M., additional, Stone, Richard M., additional, Lam, Du, additional, Wang, Xiwei, additional, Gong, Jing, additional, Kapsalis, Stephanie M., additional, Hickman, Denice, additional, Zhang, Vickie, additional, Winkler, Thomas, additional, Daigle, Scott, additional, and Vyas, Paresh, additional

Published
2019
Full Text
View/download PDF

38. Experiential Attunements in an Illuminated City at Night: A Pedagogical Writing Experiment

Author

Zhang, Vickie, primary, Kelly, David, additional, Rodriguez Castro, Laura, additional, Iaquinto, Benjamin Lucca, additional, Hughes, Ainsley, additional, Edensor, Tim, additional, McKay, Campbell, additional, Lobo, Michele, additional, Kennedy, Melissa, additional, Wolifson, Peta, additional, Ratnam, Charishma, additional, Buckle, Caitlin, additional, Dorignon, Louise, additional, Adamczyk, Elizabeth, additional, Barry, Kaya, additional, and Bissell, David, additional

Published
2019
Full Text
View/download PDF

39. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

Author

Dinardo, Courtney Denton, primary, Stein, Anthony Selwyn, additional, Stein, Eytan M., additional, Fathi, Amir Tahmasb, additional, Frankfurt, Olga, additional, Schuh, Andre C., additional, Martinelli, Giovanni, additional, Patel, Prapti Arvind, additional, Raffoux, Emmanuel, additional, Tan, Peter, additional, Zeidan, Amer Methqal, additional, de Botton, Stéphane, additional, Kantarjian, Hagop M., additional, Stone, Richard M., additional, Lam, Du Hung, additional, Gong, Jing, additional, Zhang, Vickie, additional, Winkler, Thomas, additional, Wu, Bin, additional, and Vyas, Paresh, additional

Published
2019
Full Text
View/download PDF

40. Im/mobilising the migration decision

Author

Zhang, Vickie and Zhang, Vickie

Abstract

This paper reconsiders the concept of the decision in geographical research on migration by refracting it through contemporary “mobilities” thinking. In doing so, I seek to develop an approach attentive to the way migrations take hold and persist in space and time. Whilst conceptualisations of the decision in migration have moved beyond their individualist heritage, sovereign models of strong agency remain implicit, often unintentionally conflating intention, effectiveness, cause and outcome. In contrast, I elaborate a relational understanding of the decision to conceptualise a decision’s limited efficacy in generating and sustaining a migration over time. Underscoring the neglected importance of stasis to migration, I trace corollaries of the mobilities dialectic of movement and stasis on the relation between action and outcome, emphasising the finite relevancy of any moment of decision. Focussing empirically on the story of a single migrant worker’s return migration in rural China, I draw on alternative accounts of agency – habit, lateral agency, and the agency of assemblages – to rework the migration decision into an ongoing process of affecting and being affected. Thinking with this case, I reconfigure the relationship between migration, event, decision and place, and affirm the value of the under-used mobilities optic in migration research.

Published
2018

41. Simultaneous Metabolic and Perfusion Imaging Using Hyperpolarized 13C MRI Can Evaluate Early and Dose-Dependent Response to Radiation Therapy in a Prostate Cancer Mouse Model.

Author

Qin, Hecong, Zhang, Vickie, Bok, Robert A., Santos, Romelyn Delos, Cunha, J. Adam, Hsu, I-Chow, Santos, BS, Justin Delos, Lee, Jessie E., Sukumar, Subramaniam, Larson, Peder E.Z., Vigneron, Daniel B., Wilson, David M., Sriram, Renuka, Kurhanewicz, John, and Santos, Justin Delos

Subjects
*PROSTATE cancer, *RADIOTHERAPY, *CONTRAST-enhanced magnetic resonance imaging, *PERFUSION, *DIFFUSION magnetic resonance imaging, *BIOLOGICAL models, *UREA, *TIME, *ANIMAL experimentation, *MAGNETIC resonance imaging, *RADIONUCLIDE imaging, *TREATMENT effectiveness, *DOSE-response relationship (Radiation), *CARBOXYLIC acids, *RESEARCH funding, *PROSTATE tumors, *ISOTOPES, *MICE
Abstract

Purpose: To investigate use of a novel imaging approach, hyperpolarized (HP) 13C magnetic resonance imaging (MRI) for simultaneous metabolism and perfusion assessment, to evaluate early and dose-dependent response to radiation therapy (RT) in a prostate cancer mouse model.Methods and Materials: Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mice (n = 18) underwent single-fraction RT (4-14 Gy steep dose across the tumor) and were imaged serially at pre-RT baseline and 1, 4, and 7 days after RT using HP 13C MRI with combined [1-13C]pyruvate (metabolic active agent) and [13C]urea (perfusion agent), coupled with conventional multiparametric 1H MRI including T2-weighted, dynamic contrast-enhanced, and diffusion-weighted imaging. Tumor tissues were collected 4 and 7 days after RT for biological correlative studies.Results: We found a significant decrease in HP pyruvate-to-lactate conversion in tumors responding to RT, with concomitant significant increases in HP pyruvate-to-alanine conversion and HP urea signal; the opposite changes were observed in tumors resistant to RT. Moreover, HP lactate change was dependent on radiation dose; tumor regions treated with higher radiation doses (10-14 Gy) exhibited a greater decrease in HP lactate signal than low-dose regions (4-7 Gy) as early as 1 day post-RT, consistent with lactate dehydrogenase enzyme activity and expression data. We also found that HP [13C]urea MRI provided assessments of tumor perfusion similar to those provided by 1H dynamic contrast-enhanced MRI in this animal model. However, apparent diffusion coefficien , a conventional 1H MRI functional biomarker, did not exhibit statistically significant changes within 7 days after RT.Conclusion: These results demonstrate the ability of HP 13C MRI to monitor radiation-induced physiologic changes in a timely and dose-dependent manner, providing the basic science premise for further clinical investigation and translation. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

Author

DiNardo, Courtney D., primary, Watts, Justin M., additional, Stein, Eytan M., additional, de Botton, Stephane, additional, Fathi, Amir T., additional, Prince, Gabrielle T., additional, Stein, Anthony S., additional, Foran, James M., additional, Stone, Richard M., additional, Patel, Prapti A., additional, Tallman, Martin S., additional, Choe, Sung, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Dai, David, additional, Fan, Bin, additional, Yen, Katharine E., additional, Kapsalis, Stephanie M., additional, Hickman, Denice, additional, Agresta, Samuel V., additional, Liu, Hua, additional, Wu, Bin, additional, Attar, Eyal C., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

43. Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Author

Roboz, Gail J., primary, DiNardo, Courtney D., additional, Stein, Eytan M., additional, de Botton, Stephane, additional, Mims, Alice S., additional, Prince, Gabrielle T., additional, Altman, Jessica K., additional, Arellano, Martha L., additional, Donnellan, William B., additional, Erba, Harry P., additional, Mannis, Gabriel N., additional, Pollyea, Daniel A, additional, Stein, Anthony S., additional, Uy, Geoffrey L., additional, Watts, Justin M., additional, Fathi, Amir T., additional, Kantarjian, Hagop M., additional, Tallman, Martin S., additional, Choe, Sung, additional, Dai, David, additional, Fan, Bin, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Yen, Katharine E., additional, Kapsalis, Stephanie M., additional, Hickman, Denice, additional, Liu, Hua, additional, Agresta, Samuel V., additional, Wu, Bin, additional, Attar, Eyal C., additional, and Stone, Richard M., additional

Published
2018
Full Text
View/download PDF

44. Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study

Author

DiNardo, Courtney D., primary, Stein, Eytan M., additional, de Botton, Stéphane, additional, Roboz, Gail J., additional, Altman, Jessica K., additional, Mims, Alice S., additional, Swords, Ronan, additional, Collins, Robert H., additional, Mannis, Gabriel N., additional, Pollyea, Daniel A., additional, Donnellan, Will, additional, Fathi, Amir T., additional, Pigneux, Arnaud, additional, Erba, Harry P., additional, Prince, Gabrielle T., additional, Stein, Anthony S., additional, Uy, Geoffrey L., additional, Foran, James M., additional, Traer, Elie, additional, Stuart, Robert K., additional, Arellano, Martha L., additional, Slack, James L., additional, Sekeres, Mikkael A., additional, Willekens, Christophe, additional, Choe, Sung, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Yen, Katharine E., additional, Kapsalis, Stephanie M., additional, Yang, Hua, additional, Dai, David, additional, Fan, Bin, additional, Goldwasser, Meredith, additional, Liu, Hua, additional, Agresta, Sam, additional, Wu, Bin, additional, Attar, Eyal C., additional, Tallman, Martin S., additional, Stone, Richard M., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

45. Durable Remissions with Ivosidenib inIDH1-Mutated Relapsed or Refractory AML

Author

DiNardo, Courtney D., primary, Stein, Eytan M., additional, de Botton, Stéphane, additional, Roboz, Gail J., additional, Altman, Jessica K., additional, Mims, Alice S., additional, Swords, Ronan, additional, Collins, Robert H., additional, Mannis, Gabriel N., additional, Pollyea, Daniel A., additional, Donnellan, Will, additional, Fathi, Amir T., additional, Pigneux, Arnaud, additional, Erba, Harry P., additional, Prince, Gabrielle T., additional, Stein, Anthony S., additional, Uy, Geoffrey L., additional, Foran, James M., additional, Traer, Elie, additional, Stuart, Robert K., additional, Arellano, Martha L., additional, Slack, James L., additional, Sekeres, Mikkael A., additional, Willekens, Christophe, additional, Choe, Sung, additional, Wang, Hongfang, additional, Zhang, Vickie, additional, Yen, Katharine E., additional, Kapsalis, Stephanie M., additional, Yang, Hua, additional, Dai, David, additional, Fan, Bin, additional, Goldwasser, Meredith, additional, Liu, Hua, additional, Agresta, Sam, additional, Wu, Bin, additional, Attar, Eyal C., additional, Tallman, Martin S., additional, Stone, Richard M., additional, and Kantarjian, Hagop M., additional

Published
2018
Full Text
View/download PDF

46. AGILE: A phase 3, multicenter, randomized, placebo-controlled study of ivosidenib in combination with azacitidine in adult patients with previously untreated acute myeloid leukemia with an IDH1 mutation.

Author

Stein, Eytan, primary, Dinardo, Courtney Denton, additional, Jang, Jun Ho, additional, Miyazaki, Yasushi, additional, Ovilla Martinez, Roberto, additional, Auer, Julia, additional, Zhang, Vickie, additional, Koralek, Daniel O., additional, and Wu, Bin, additional

Published
2018
Full Text
View/download PDF

47. Ivosidenib or Enasidenib Combined with Standard Induction Chemotherapy Is Well Tolerated and Active in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation: Initial Results from a Phase 1 Trial

Author

Stein, Eytan M., primary, DiNardo, Courtney D., additional, Mims, Alice S., additional, Savona, Michael R., additional, Pratz, Keith, additional, Stein, Anthony S., additional, Fathi, Amir T., additional, Stone, Richard M., additional, Pollyea, Daniel A., additional, Odenike, Olatoyosi, additional, Lowenberg, Bob, additional, Döhner, Hartmut, additional, Schiller, Gary J., additional, Gupta, Ira V., additional, Nabhan, Salah, additional, Zhang, Vickie, additional, Almon, Caroline, additional, Cooper, Michael, additional, and Tallman, Martin S., additional

Published
2017
Full Text
View/download PDF

50. Abstract P5-19-24: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis

Author

Juric, Dejan, primary, Hamilton, Erika, additional, Garcia Estévez, Laura, additional, De Boer, Richard H, additional, Mayer, Ingrid, additional, Campone, Mario, additional, Asano, Shizuka, additional, Bhansali, Suraj, additional, Zhang, Vickie, additional, Hewes, Becker, additional, and Munster, Pamela, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results